Intermediate-term outcomes of complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients
Guillaume Coutance, Jon Kobashigawa, E. Kransdorf, Alexandre Loupy, Eva Désiré, M. Kittleson, J. Patel
Topics & Concepts
MedicineEculizumabHazard ratioPanel reactive antibodyHeart transplantationClinical endpointConfidence intervalInternal medicineTransplantationIncidence (geometry)Surrogate endpointAntibodyGastroenterologyClinical trialImmunologyCardiologyComplement systemKidney transplantationOpticsPhysicsTransplantation: Methods and OutcomesRenal Transplantation Outcomes and TreatmentsComplement system in diseases